A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: a case report and literature review
Article in Pathology - Research and Practice (July 2024)
The most recent citing publications are shown below. View all 195 publications that cite this research output on Dimensions.
Article in Pathology - Research and Practice (July 2024)
Article in World Journal of Gastroenterology (May 2024)
Article in Clinical and Translational Medicine (April 2024)